Investment Analysts’ Recent Ratings Updates for Solventum (SOLV)

Solventum (NYSE: SOLV) has recently received a number of price target changes and ratings updates:

• 5/6/2026 – Solventum had its price target lowered by UBS Group AG from $82.00 to $78.00. They now have a “neutral” rating on the stock.
• 5/6/2026 – Solventum had its price target lowered by Stifel Nicolaus from $105.00 to $90.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Solventum had its price target raised by KeyCorp from $92.00 to $93.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Solventum had its price target lowered by Wells Fargo & Company from $83.00 to $70.00. They now have an “equal weight” rating on the stock.
• 5/6/2026 – Solventum had its “buy” rating reaffirmed by BTIG Research. They now have a $89.00 price target on the stock.
• 4/27/2026 – Solventum had its price target lowered by KeyCorp from $99.00 to $92.00. They now have an “overweight” rating on the stock.
• 4/17/2026 – Solventum had its price target lowered by Piper Sandler from $98.00 to $92.00. They now have an “overweight” rating on the stock.
• 3/24/2026 – Solventum is now covered by Rothschild & Co Redburn. They set a “sell” rating and a $60.00 price target on the stock.
• 3/18/2026 – Solventum was upgraded by Wells Fargo & Company to “hold”.
• 3/8/2026 – Solventum was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell acquired 1,475 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is owned by company insiders.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.